Assembly Biosciences, Inc. (ASMB) - NASDAQ
  • Jun. 16, 2014, 12:45 PM
    | Jun. 16, 2014, 12:45 PM | 4 Comments
  • Jun. 5, 2014, 12:49 PM
    | Jun. 5, 2014, 12:49 PM | 2 Comments
  • Jun. 5, 2014, 12:01 PM
    • Shares of pico cap Ventrus Biosciences (VTUS +19.5%) jump on 3x higher volume. Today's action follows a breakout on May 29 when prices popped 23% on 14-fold surge in volume.
    • Traders appear to be taking positions before the company's pre-IND meeting with the FDA on June 19 where the parties will discuss guidance regarding an approval path for Dolizem (diltiazem hydrochloride cream) as a treatment for anal fissures. Based on a positive outcome of the meeting, Ventrus plans to file an NDA in 2H 2014 with an expected PDUFA date about a year later.
    • On February 12, shares cratered 61% on turnover of 18M shares after the firm reported that Dolizem failed to outperform placebo in a second Phase 3 trial. In the first Phase 3, the product did demonstrate a statistically significant improvement in pain versus placebo.
    • The company's previously-announced merger with Assembly Pharmaceuticals will close around July 10. The name of the combined firm will be Assembly Biosciences trading under the ticker "ASMB."
    | Jun. 5, 2014, 12:01 PM
  • May 29, 2014, 12:47 PM
    | May 29, 2014, 12:47 PM | 2 Comments
  • May 19, 2014, 12:45 PM
    | May 19, 2014, 12:45 PM
  • Feb. 12, 2014, 9:54 AM
    • Ventrus Biosciences' (VTUS) shares collapse 61% after its Diltiazem Cream for patients with anal fissures failed to lower pain more than a placebo in a Phase III trial.
    • Diltiazem is designed to reduce pain associated with or following defecation by dilating the blood vessels that supply the associated region. (Previous)
    | Feb. 12, 2014, 9:54 AM
  • Feb. 12, 2014, 9:10 AM
    | Feb. 12, 2014, 9:10 AM
  • Sep. 11, 2013, 12:45 PM
    | Sep. 11, 2013, 12:45 PM | 5 Comments
  • Sep. 11, 2013, 9:10 AM
    | Sep. 11, 2013, 9:10 AM | 1 Comment
  • Sep. 11, 2013, 8:49 AM
    • Ventrus Biosciences (VTUS) says two clinical dermal safety studies of VEN 307 demonstrate the treatment is safe and well tolerated.
    • No serious AE's were reported.
    • All pharmacokinetic parameters were met in a separate study, consistent with an earlier investigator sponsored trial.
    • The data "mark another important step in [the] effort to develop and commercialize [the drug]," CEO Russell Ellison says.
    • VEN 307 is currently in a second pivotal Phase 3 trial. (PR)
    • Shares +12% premarket.
    | Sep. 11, 2013, 8:49 AM
  • Jan. 30, 2013, 12:45 PM
    Midday top 10 gainers: MERU +40%. CWBC +21%. BIOC +19%. MGAM +17%. FSL +17%. HTCH +17%. DLHC +17%. CPNO +14%. USAK +14%. IBCP +14%.
    Midday top 10 Losers: VTUS -21%. KTCC -18%. MTOR -16%. HA -13%. ATTU -12%. CODE -12%. CEVA -12%. AUDC -11%. TRMD -10%. UPI -9%.
    | Jan. 30, 2013, 12:45 PM | 3 Comments
  • Jan. 29, 2013, 5:45 PM

    Ventrus Biosciences (VTUS) announces a concurrent secondary offering to sell shares of its common stock, and shares of its Series A Convertible Preferred Stock in a separate underwritten public offering. Shares -7% AH.

    | Jan. 29, 2013, 5:45 PM
  • Jan. 29, 2013, 12:45 PM
    Midday top 10 gainers: MLNK +32%. KERX +30%. SOMH +25%. VTUS +24%. MHH +14%. SWIR +14%. AEZS +11%. CNIT +11%. IBCP +10%. SSBI +10%.
    Midday top 10 Losers: OXF -31%. ANAC -21%. VMW -20%. SANM -18%. OCZ -18%. LXK -15%. CTC -13%. GIG -12%. NTGR -11%. SHIP -11%.
    | Jan. 29, 2013, 12:45 PM
  • Jan. 29, 2013, 12:44 PM
    Ventrus Biosciences (VTUS +26%) continues on a tear today, extending gains for a second day after the biotech company confirmed last week that it has sufficient cash to complete development of VEN307, its anal fissure drug candidate.
    | Jan. 29, 2013, 12:44 PM
  • Nov. 14, 2012, 2:35 PM

    Ventrus Biosciences (VTUS +5.3%) moves higher today, offsetting some of the losses from a lower than expected Q3 EPS yesterday. Cantor Fitzgerald thinks the results were "meaningless" and the stock is extremely undervalued. The firm believes the market is too deeply discounting the company's diltiazem hydrochloride cream, a treatment for anal fissures currently in Phase 3 testing. The drug suffered a setback recently when the FDA said it required a second Phase 3 study, but Cantor believes it should be market ready by the end of 2014.

    | Nov. 14, 2012, 2:35 PM
  • Nov. 5, 2012, 3:24 PM

    Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase 3 study of its diltiazem hydrochloride cream - a treatment for anal fissures - before any new drug application can be filed. The drug developer says it expects to file the NDA following completion of the second Phase 3 study, with results expected early Q4 2013, and expects to file an NDA late in Q4 2013 with an anticipated PDUFA date near the end of 2014.

    | Nov. 5, 2012, 3:24 PM
Company Description
Assembly Biosciences, Inc. operates as a biopharmaceutical company which develops novel treatments for hepatitis B virus infection and C. difficile-associated diarrhea. It specializes in the development of therapies for infectious diseases like HIV, CDAD and other disorders of the... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States